CHIRAL, FLUORINE-CONTAINING PHARMACEUTICALS(Review)

• Date: 2025
• Author Affiliations: Jianlin Han — Jiangsu Co-Innovation Center of Efficient Processing and Utilization of Forest Resources, College of Chemical Engineering, Nanjing Forestry University, Nanjing 210037, China; Alicja Wzorek — Institute of Chemistry, Jan Kochanowski University in Kielce, Uniwersytecka 7, 25-406 Kielce, Poland; Gagan Dhawan — School of Allied Medical Sciences, Delhi Skill and Entrepreneurship University, Dwarka, New Delhi-110077, India; Wei Zhang — Department of Chemistry, University of Massachusetts Boston, Boston MA 02125, Unites States;; Alexander Sorochinsky — Department of Fine Organic Synthesis, V.P. Kukhar Institute of Bioorganic Chemistry and Petrochemistry, The National Academy of Sciences of Ukraine, 1 Murmanska str., Kyiv 02094, Ukraine; Daniel Baecker — Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Freie Universität Berlin, Königin-Luise-Straße 2+4, 14195 Berlin, Germany; Taizo Ono — National Institute of Advanced Industrial Science and Technology, 463-8560, Nagoya, Japan; Karel Klika — Molecular Structure Analysis, German Cancer Research Center (DKFZ), ImNeuenheimer Feld 280, 69120 Heidelberg, Germany; Vadim Soloshonok — University of Basque Country
• Keywords: keywords
• Main Authors: Han, Jianlin, Wzorek, Alicja, Dhawan, Gagan, Zhang, Wei, Sorochinsky, Alexander, Baecker, Daniel, Ono, Taizo, Klika, Karel, Soloshonok, Vadim
• Format: Article
• Language: English
• Published: V.I.Vernadsky Institute of General and Inorganic Chemistry 2025
• Online Access: https://ucj.org.ua/index.php/journal/article/view/710
• Journal Title: Ukrainian Chemistry Journal

Fluorine is a key element in drug design due to its ability to enhance metabolic stability, binding affinity, and bioavailability. Fluorine’s properties lead to more stable drugs with longer half-lives, reducing dosing frequency and improving patient compliance. Its small size and high electronegati...